Minocycline Significantly Improves Functional Recovery in Acute Ischaemic Stroke: Evidence from the EMPHASIS Trial
Posted inInternal Medicine Neurology news

Minocycline Significantly Improves Functional Recovery in Acute Ischaemic Stroke: Evidence from the EMPHASIS Trial

The EMPHASIS trial reveals that oral minocycline initiated within 72 hours of an acute ischaemic stroke significantly enhances functional independence at 90 days. This multicentre study provides robust evidence for a well-tolerated, accessible neuroprotective strategy beyond the traditional reperfusion window.
Long-Term Benfotiamine Treatment Fails to Improve Diabetic Polyneuropathy: Insights from the BOND Randomized Controlled Trial
Posted inDiabetes & Endocrinology Neurology news

Long-Term Benfotiamine Treatment Fails to Improve Diabetic Polyneuropathy: Insights from the BOND Randomized Controlled Trial

The 12-month BOND study found that high-dose benfotiamine (600 mg daily) did not significantly improve corneal nerve fiber length or other neurophysiological markers in patients with type 2 diabetes and symptomatic polyneuropathy, despite successfully increasing systemic thiamine levels.
Long-Term Ublituximab Therapy in Multiple Sclerosis: Five-Year Results from the ULTIMATE I and II Extension Study Validate Early High-Efficacy Intervention
Posted inNeurology news

Long-Term Ublituximab Therapy in Multiple Sclerosis: Five-Year Results from the ULTIMATE I and II Extension Study Validate Early High-Efficacy Intervention

Five-year data from the ULTIMATE I and II open-label extension demonstrate that ublituximab maintains exceptionally low relapse rates and slows disability progression in relapsing multiple sclerosis, emphasizing the clinical superiority of early and sustained B-cell depletion therapy.
Recombinant Factor VIIa Fails to Improve Functional Outcomes in Hyperacute Intracerebral Haemorrhage Despite Reduced Bleeding: Results from the FASTEST Trial
Posted inEmergency Medicine Neurology news

Recombinant Factor VIIa Fails to Improve Functional Outcomes in Hyperacute Intracerebral Haemorrhage Despite Reduced Bleeding: Results from the FASTEST Trial

The FASTEST trial demonstrated that while recombinant factor VIIa administered within two hours of intracerebral haemorrhage onset significantly reduced hematoma growth, it failed to improve functional outcomes at 180 days and increased the risk of life-threatening thromboembolic events.
Delirium as a Sentinel Event: New UK Biobank Data Links Acute Brain Failure to Decades of Multisystem Vulnerability
Posted inInternal Medicine Neurology news

Delirium as a Sentinel Event: New UK Biobank Data Links Acute Brain Failure to Decades of Multisystem Vulnerability

A large-scale matched cohort study from the UK Biobank identifies in-hospital delirium as a sentinel marker for long-term multisystem vulnerability. Associated with increased risks of sepsis, AKI, and falls, delirium signals a profound physiological decline that persists independently of pre-existing frailty or dementia.